LCAR-F33S

LCAR-F33S is a genetically modified autologous T cell therapy, specifically a CAR-T cell product engineered to recognize and target malignant plasma cells in patients with relapsed or refractory multiple myeloma. The therapeutic process involves collecting the patient's T cells, genetically modifying them to express a chimeric antigen receptor (CAR) that directs specificity toward myeloma cells, expanding the modified cells, and then infusing them back into the patient. The mechanism of action is driven by targeted cytotoxicity induced by CAR-expressing T cells against multiple myeloma cells. The therapy is being evaluated in a prospective, single-arm, open-label clinical trial to assess safety, tolerability, pharmacokinetics, and antitumor efficacy[1][3][5].